|drug3897||high flow nasal cannula (HFNC) Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D055371||Acute Lung Injury NIH||0.09|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.08|
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS. Based on the potential beneficial mechanisms of HFNC and PP, whether early use of prone positioning combined with HFNC can avoid the need for intubation in COVID-19 induced moderate to severe ARDS patients needs to be further investigated.
Description: the treatment failure rate of HFNC/HFNC+PP support and clinical requirement for advanced respiratory supportMeasure: Treatment failure Time: 28 days
Description: the improvement of SpO2/FIO2 or PaO2/FiO2 from HFNC alone to HFNC+PPMeasure: Efficacy of PP Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports